​Research Studies

​CARDIOVASCULAR: 

If you have Dyslipidemia and are a high risk for cardiovascular disease you may qualify for clinical trial.

KIDNEY:

If you have anemia due to chronic kidney disease and are either on dialysis or not on dialysis, you may qualify for clinical trial.

• Diabetes    
• Cardiovascular
  
• Liver    
• Podiatry    
• Medical Device     
• Women's Health    
• Hypertension
• Men's Health
• Hyperlipidemia

DIABETES:
Have you been diagnosed with Diabetes?

If you are controlling your sugar levels with exercise and diet only, you may qualify for a clinical trial!

Clinical Trial Studies We Specialize In

clinical trials research Studies

For Information:

NewPhase Clinical Trials has an established history of working with many pharmaceutical companies, including: Pfizer, Allergan, Amgen, Parexel, Sanofi, AstraZeneca, Britol-Myers Squibb, Covance, Eli Lilly, GlaxoSmithKline, Gilead Sciences, Icon, Integrium, Merck, Trividia Health, Novartis, Pharmacosmos, Abbot, Akebia and Takeda Pharmaceutical, Derma Sciences, ACELL, Tasly Pharmaceuticals among others. 

​CURRENT STUDIES:

Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an Outpatient Setting for Heart Failure (LANAIS-HF).  Abbott Laboratories

RECENTLY CLOSED STUDIES:

Evolocumab Study: Getting to an improved Understanding of LDL-C and Dyslipidemia management (GOULD): a Registry of High Cardiovascular Risk Patients in the United States  Amgen 

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) AKB-6548-CI-0014 AKEBIA 

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) AKB-6548-CI-0015 AKEBIA 

Phase 3, Randomized, Open Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Incident Dialysis-Dependent Chronic Kidney Disease (DD-CKD). (INNO2VATE-CORRECTION) AKB-6548-CI-0016  AKEBIA

Phase 3, Randomized, Open Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Incident Dialysis-Dependent Chronic Kidney Disease (DD-CKD). (INNO2VATE-CONVERSION) AKB-6548-CI-0017  AKEBIA

Phase 1b, Randomized, Open Label , Study to Evaluate the Pharmacokinetics, Pharmacodynamic and Safety of Vadadustat in Hemodialysis Subjects with Anemia Associated with Chronic Kidney Disease. AKB-6548-CI-CI0034.

AKEBIA

A 16-Week Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily PF-06882961 Administration in Adults with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise. C3421005.  PFIZER

​